The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

Objective: To determine the efficacy of donepezil in the treatment of neuropsychiatric symptoms in patients with Alzheimer disease (AD) in a randomized withdrawal study. Method: Patients with mild to moderate AD with marked neuropsychiatric symptoms at baseline (Neuropsychiatric Inventory [NPI] > 11 points) were treated openly with donepezil 5 mg daily for 6 weeks followed by 10 mg daily for a further 6 weeks. Patients were then randomized (60:40) to either placebo or 10 mg donepezil daily. All patients were assessed at 6 weeks and provided there was no marked cognitive deterioration their blinded treatment was continued for a further 6 weeks. NPI and carer distress were assessed at 6 weekly intervals throughout the study. Results: A total of 134 patients participated. Following randomization patients who continued on donepezil 10 mg for 12 weeks had improvements in NPI compared with the placebo group (mean change −2.9 vs 3.3 points; ITT-LOCF p = 0.02) and in NPI-Distress scores (median change −2.0 vs 1.0 points; ITT-LOCF p = 0.01). During the open-label phase the total NPI and NPI-Distress scores were lower after 12 weeks treatment with open label donepezil compared with baseline (total NPI 22 points vs13 points; ITT-LOCF p < 0.0001; NPI-Distress 13.5 vs 7.9 points; ITT-LOCF p < 0.0001). In the open-label phase all domains of the NPI (with the exception of elation) were improved (all p < 0.05 after Bonferroni correction). Conclusions: Donepezil has significant efficacy in the treatment of neuropsychiatric symptoms in patients with mild to moderate AD.

[1]  J. Cummings.  Cholinesterase inhibitors: A new class of psychotropic compounds. , 2000, The American journal of psychiatry.

[2]  S. Lovestone,et al.  Do neuroleptic drugs hasten cognitive decline in dementia? , 1997, BMJ.

[3]  M. Esiri,et al.  Cholinergic deficits contribute to behavioral disturbance in patients with dementia , 2000, Neurology.

[4]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[5]  Bruno Vellas,et al.  Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer's Disease , 2002, International Psychogeriatrics.

[6]  B. Lawlor,et al.  A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia , 1999, Neurology.

[7]  P. Tariot,et al.  Mental disorders in the nursing home: another perspective. , 1993, The American journal of psychiatry.

[8]  Robert Howard,et al.  Guidelines on drug treatments for Alzheimer's disease , 1997, The Lancet.

[9]  B. Gordon,et al.  Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. , 2001, Archives of neurology.

[10]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[11]  M. Folstein,et al.  Prevalence of mental illness in a community nursing home. , 1986, The American journal of psychiatry.

[12]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[13]  L. Schneider,et al.  Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? , 2001, International journal of geriatric psychiatry.

[14]  M. Weiner,et al.  Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. , 2000, The Journal of clinical psychiatry.

[15]  Issues in drug treatment for Alzheimer's disease , 1997, The Lancet.

[16]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[17]  J. Cummings,et al.  The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. , 2000, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[18]  Kristine Yaffe,et al.  Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. , 2003, JAMA.

[19]  P. Tariot,et al.  A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting , 2001, Journal of the American Geriatrics Society.